Yutiq, a non-bioerodible intravitreal micro-insert containing 0.18 mg fluocinolone acetonide, received FDA approval for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, said in a press release that the company plans to launch Yutiq in the first quarter of 2019.
“The approval of Yutiq by the FDA is a significant milestone achieved by the company and marks the second approved ophthalmic product in our pipeline that we plan to commercialize ourselves in the U.S.,” Lurker said in the
Uncategorized